Thomas VanCott, PhD - 2022 World Medical Innovation Forum
Thomas VanCott
This speaker appears at this event:

Thomas VanCott, PhD

Chief Technology & Strategy Officer, Catalent Cell & Gene Therapy

Dr. VanCott joined Catalent through its acquisition of Paragon Gene Therapy in 2019. Prior to Paragon he spent 14 years as the President and CEO of Advanced Bioscience Laboratories Inc. (ABL), and previously held several positions at the Henry M. Jackson Foundation for the Advancement of Military Medicine. Dr. VanCott received a doctorate in physical chemistry from the University of Virginia, and a bachelor’s degree in chemistry from Dickinson College, Carlisle, Pennsylvania.